Literature DB >> 8303211

A prospective study of first attacks of inflammatory bowel disease and non-relapsing colitis. Microbiologic findings.

G Schumacher1, B Kollberg, B Sandstedt, C Jorup, L Grillner, A Ljungh, R Möllby.   

Abstract

In 105 patients with a first attack of colitis, thorough microbiologic investigations of rectal biopsy, faecal, and serum samples were performed with the aims of identifying the colitis-causing agents and shedding light on factors that may precipitate or aggravate the onset of inflammatory bowel disease. Sixty-one patients were found to have inflammatory bowel disease. In 13 (21%) of these patients microbial findings were positive. Eight of the 61 patients fell ill during or immediately after antibiotic treatment, and 10 while travelling abroad. Forty-one of the 105 patients had non-relapsing colitis. In 32 (78%) of these the microbial findings were positive. Six of these 41 patients fell ill during or immediately after antibiotic treatment, and 14 while travelling abroad. Alteration of the intestinal microflora on travelling, gastrointestinal infection, or treatment with antibiotics seems to precipitate or aggravate the symptoms in latent inflammatory bowel disease. In such patients the mode of onset is often changed from insidious to more acute, which may cause difficulty in differentiation from non-relapsing colitis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8303211     DOI: 10.3109/00365529309098313

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  10 in total

Review 1.  Crohn's disease and infections: a complex relationship.

Authors:  Gert De Hertogh; Karel Geboes
Journal:  MedGenMed       Date:  2004-08-10

Review 2.  Chronic inflammatory bowel disease.

Authors:  N K Mittal; B S Kirschner
Journal:  Indian J Pediatr       Date:  1994 Nov-Dec       Impact factor: 1.967

3.  Seasonal variations in the onset of ulcerative colitis.

Authors:  B Moum; E Aadland; A Ekbom; M H Vatn
Journal:  Gut       Date:  1996-03       Impact factor: 23.059

4.  Helicobacter bilis colonization enhances susceptibility to Typhlocolitis following an inflammatory trigger.

Authors:  Zhiping Liu; Amanda E Ramer-Tait; Abigail L Henderson; Cumhur Yusuf Demirkale; Dan Nettleton; Chong Wang; Jesse M Hostetter; Albert E Jergens; Michael J Wannemuehler
Journal:  Dig Dis Sci       Date:  2011-04-19       Impact factor: 3.199

5.  The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease?

Authors:  Justyna Bien; Vindhya Palagani; Przemyslaw Bozko
Journal:  Therap Adv Gastroenterol       Date:  2013-01       Impact factor: 4.409

6.  Expression of binding of plasminogen, thrombospondin, vitronectin, and fibrinogen, and adhesive properties by Escherichia coli strains isolated from patients with colonic diseases.

Authors:  W Shen; H Steinrück; A Ljungh
Journal:  Gut       Date:  1995-03       Impact factor: 23.059

7.  Antibiotic-associated diarrhea: candidate organisms other than Clostridium difficile.

Authors:  Hyun Joo Song; Ki-Nam Shim; Sung-Ae Jung; Hee Jung Choi; Mi Ae Lee; Kum Hei Ryu; Seong-Eun Kim; Kwon Yoo
Journal:  Korean J Intern Med       Date:  2008-03       Impact factor: 2.884

8.  Seasonal variations in onset and exacerbation of inflammatory bowel diseases in children.

Authors:  Rajmohan Dharmaraj; Anas Jaber; Rajan Arora; Karen Hagglund; Hernando Lyons
Journal:  BMC Res Notes       Date:  2015-11-20

9.  Acute Infectious Gastroenteritis Potentiates a Crohn's Disease Pathobiont to Fuel Ongoing Inflammation in the Post-Infectious Period.

Authors:  Cherrie L Small; Lydia Xing; Joseph B McPhee; Hong T Law; Brian K Coombes
Journal:  PLoS Pathog       Date:  2016-10-06       Impact factor: 6.823

10.  Challenges in the diagnosis of ulcerative colitis with concomitant bacterial infections and chronic infectious colitis.

Authors:  Wei-Chen Lin; Chen-Wang Chang; Ming-Jen Chen; Cheng-Hsin Chu; Shou-Chuan Shih; Tzu-Chi Hsu; Horng-Yang Wang
Journal:  PLoS One       Date:  2017-12-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.